Investor Relations


Welcome to Trovagene Investor Relations

Corporate Profile

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally. 

Trovagene Corporate Presentation
August 4, 2016
2:00pm PDT

rovagene will report financial results for the second quarter 2016 on Thursday,August 4, 2016 at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time). Trovagene’s senior management...

August 10, 2016 - August 12, 2016

Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D. will present a corporate overview at the Precision Medicine Leaders Summit 2016 taking place August 10-12th, 2016 at the Manchester Grand...

September 14, 2016 - September 15, 2016

Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D. will be presenting at the 2nd Annual Precision Medicine Congress taking place September 14-15th, 2016 at the London Heathrow Marriott...

print email